Because of the dearth of targeted treatments in China, patients with relapsed/refractory (R/R) NHL, multiple myeloma, or ALL continue to be prescribed salvage chemotherapy in later lines of treatment. Ongoing reforms in China’s regulatory landscape, such as breakthrough therapy designation and priority review pathway, are encouraging domestic and international companies to develop innovative treatments such as CAR T-cell therapies for R/R patients. Many such therapies are in clinical trials in China, and some—such as axicabtagene ciloleucel (Fosun Kite’s Yescarta), tisagenlecleucel (Novartis’s Kymriah), and JWCAR029 (JW Therapeutics)—are expected to launch there in the next few years. We anticipate that China will become a market leader in CAR T-cell therapies during the forecast period.
- How much of China’s population is suitable to receive CAR T-cell treatment, and how will drug-treatment rates change during the forecast period?
- Which will be the most commercially relevant CAR T-cell therapies in China and why? What are interviewed experts’ insights into these therapies? Which clinical unmet needs will they fulfill?
- What are the market access considerations for key CAR T-cell therapies in China? What sales / uptake could these agents secure?
- What are the key drivers of and constraints in China’s CAR T-cell therapy market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists.
Diagnosed incidence of non-Hodgkin’s lymphoma, multiple myeloma, and acute lymphoblastic leukemia in urban versus rural China. Clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient share of key CAR T-cell therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 3 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products.
- CAR-T Cell Therapies - China In-Depth - CAR T-cell Therapy - China In-Depth (China)
- CAR T-cell Therapy - China In-Depth (China)
Author(s): Karan Verma, M.Sc.; Pramilesh Tekchand Suryawanshi
Karan Verma, M.Sc., is a senior analyst on the China In-Depth team at DRG, part of Clarivate. He is involved in primary and secondary market research to create syndicated landscape and forecast content and provide Chinese market-specific insights in various therapy areas, including hepatocellular carcinoma, multiple myeloma, non-Hodgkin’s lymphoma, migraine, type 2 diabetes, and multiple sclerosis. He has expertise in market forecasting, competitive intelligence, benchmarking, and brand performance analytics. He obtained his M.Sc. in biomedical engineering from the University of Warwick in Coventry, United Kingdom, and a B.E. in biomedical engineering from Maharshi Dayanand University in Haryana, India.
Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Before joining DRG, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.